abstract: BACKGROUND: @entity8 ( @entity8 ) are among the most common complications in @entity0 with @entity1 . In such @entity0 with @entity2 , the most serious expression of @entity3 in Japan is acute exacerbation of @entity8 caused by anticancer treatment. Nevertheless, there has been no consensus and no evidence presented, regarding optimal treatment for advanced @entity1 with IIP. @entity0 AND METHODS: Chemotherapy-naive @entity0 with advanced @entity4 ( @entity4 ) with IIP who were ineligible for curative radiotherapy were enrolled. @entity0 received @entity7 every 21 days at a dose of area under the curve 6.0 on day 1 and @entity6 at a dose of 100 mg/m on days 1 to 3. RESULTS: Between July 2002 and October 2008, 17 @entity0 with @entity4 with IIP, including 14 @entity0 , eight of whom were diagnosed with @entity5 , were enrolled and treated for a mean of 3.5 cycles of @entity7 plus @entity6 . One @entity0 (5.9%; 95% confidence interval, 0-18.4%) with clinically confirmed @entity5 had acute exacerbation of @entity8 associated with the treatment. The overall response rate was 88.2%. The median progression-free survival, median survival time, and 1-year survival rate were 5.5 months, 8.7 months, and 29.4%, respectively. CONCLUSION: This is the first report indicating that @entity0 with advanced @entity4 with @entity8 may benefit from chemotherapy. @entity0 with advanced @entity4 with IIP treated with @entity6 and @entity7 combination chemotherapy gain benefits, with safety equivalent to that seen in @entity0 without IIP. The results from this study would support, on ethical grounds, the conduct of a large-scale study to evaluate this regimen.

title: The feasibility study of @entity7 plus @entity6 for advanced XXXX with @entity8 .

answer: @entity4


abstract: BACKGROUND: @entity8 ( @entity8 ) are among the most common complications in @entity0 with @entity1 . In such @entity0 with @entity2 , the most serious expression of @entity3 in Japan is acute exacerbation of @entity8 caused by anticancer treatment. Nevertheless, there has been no consensus and no evidence presented, regarding optimal treatment for advanced @entity1 with IIP. @entity0 AND METHODS: Chemotherapy-naive @entity0 with advanced @entity4 ( @entity4 ) with IIP who were ineligible for curative radiotherapy were enrolled. @entity0 received @entity7 every 21 days at a dose of area under the curve 6.0 on day 1 and @entity6 at a dose of 100 mg/m on days 1 to 3. RESULTS: Between July 2002 and October 2008, 17 @entity0 with @entity4 with IIP, including 14 @entity0 , eight of whom were diagnosed with @entity5 , were enrolled and treated for a mean of 3.5 cycles of @entity7 plus @entity6 . One @entity0 (5.9%; 95% confidence interval, 0-18.4%) with clinically confirmed @entity5 had acute exacerbation of @entity8 associated with the treatment. The overall response rate was 88.2%. The median progression-free survival, median survival time, and 1-year survival rate were 5.5 months, 8.7 months, and 29.4%, respectively. CONCLUSION: This is the first report indicating that @entity0 with advanced @entity4 with @entity8 may benefit from chemotherapy. @entity0 with advanced @entity4 with IIP treated with @entity6 and @entity7 combination chemotherapy gain benefits, with safety equivalent to that seen in @entity0 without IIP. The results from this study would support, on ethical grounds, the conduct of a large-scale study to evaluate this regimen.

title: The feasibility study of XXXX plus @entity6 for advanced @entity4 with @entity8 .

answer: @entity7


abstract: BACKGROUND: @entity8 ( @entity8 ) are among the most common complications in @entity0 with @entity1 . In such @entity0 with @entity2 , the most serious expression of @entity3 in Japan is acute exacerbation of @entity8 caused by anticancer treatment. Nevertheless, there has been no consensus and no evidence presented, regarding optimal treatment for advanced @entity1 with IIP. @entity0 AND METHODS: Chemotherapy-naive @entity0 with advanced @entity4 ( @entity4 ) with IIP who were ineligible for curative radiotherapy were enrolled. @entity0 received @entity7 every 21 days at a dose of area under the curve 6.0 on day 1 and @entity6 at a dose of 100 mg/m on days 1 to 3. RESULTS: Between July 2002 and October 2008, 17 @entity0 with @entity4 with IIP, including 14 @entity0 , eight of whom were diagnosed with @entity5 , were enrolled and treated for a mean of 3.5 cycles of @entity7 plus @entity6 . One @entity0 (5.9%; 95% confidence interval, 0-18.4%) with clinically confirmed @entity5 had acute exacerbation of @entity8 associated with the treatment. The overall response rate was 88.2%. The median progression-free survival, median survival time, and 1-year survival rate were 5.5 months, 8.7 months, and 29.4%, respectively. CONCLUSION: This is the first report indicating that @entity0 with advanced @entity4 with @entity8 may benefit from chemotherapy. @entity0 with advanced @entity4 with IIP treated with @entity6 and @entity7 combination chemotherapy gain benefits, with safety equivalent to that seen in @entity0 without IIP. The results from this study would support, on ethical grounds, the conduct of a large-scale study to evaluate this regimen.

title: The feasibility study of @entity7 plus @entity6 for advanced @entity4 with XXXX .

answer: @entity8


abstract: BACKGROUND: @entity8 ( @entity8 ) are among the most common complications in @entity0 with @entity1 . In such @entity0 with @entity2 , the most serious expression of @entity3 in Japan is acute exacerbation of @entity8 caused by anticancer treatment. Nevertheless, there has been no consensus and no evidence presented, regarding optimal treatment for advanced @entity1 with IIP. @entity0 AND METHODS: Chemotherapy-naive @entity0 with advanced @entity4 ( @entity4 ) with IIP who were ineligible for curative radiotherapy were enrolled. @entity0 received @entity7 every 21 days at a dose of area under the curve 6.0 on day 1 and @entity6 at a dose of 100 mg/m on days 1 to 3. RESULTS: Between July 2002 and October 2008, 17 @entity0 with @entity4 with IIP, including 14 @entity0 , eight of whom were diagnosed with @entity5 , were enrolled and treated for a mean of 3.5 cycles of @entity7 plus @entity6 . One @entity0 (5.9%; 95% confidence interval, 0-18.4%) with clinically confirmed @entity5 had acute exacerbation of @entity8 associated with the treatment. The overall response rate was 88.2%. The median progression-free survival, median survival time, and 1-year survival rate were 5.5 months, 8.7 months, and 29.4%, respectively. CONCLUSION: This is the first report indicating that @entity0 with advanced @entity4 with @entity8 may benefit from chemotherapy. @entity0 with advanced @entity4 with IIP treated with @entity6 and @entity7 combination chemotherapy gain benefits, with safety equivalent to that seen in @entity0 without IIP. The results from this study would support, on ethical grounds, the conduct of a large-scale study to evaluate this regimen.

title: The feasibility study of @entity7 plus XXXX for advanced @entity4 with @entity8 .

answer: @entity6


abstract: BACKGROUND: Among many aspects, wound healing depends on early restoration of venous blood flow across wound margins. The type of surgical occlusion of @entity0 during operations was assumed to have an influence on the early postoperative reunion of @entity0 and thereby on wound healing. Currently, there are different methods of vein stump occlusion available: ligation (e.g., Vicryl), closure using metal clips (e.g., LigaClip), coagulation using manually controlled @entity2 , and the use of a computer-controlled bipolar system (e.g., BiClamp). The aim of this study was to surgically and histologically compare the healing process, including new vessel formation after vein occlusion using one of the methods listed. METHODS: In a @entity1 model (n = 50), both jugular and femoral veins were prepared, occluded twice with one of the methods mentioned above (i.e., 400 occlusions), and finally cut in-between. Groups of 10 animals were reoperated and evaluated surgically and histologically after 5 days, 10 days, 15 days, 30 days, and 90 days. RESULTS: Occlusion methods using Vicryl, LigaClip, or @entity2 allow highly reliable vessel occlusion. Surgical evaluation showed higher occurrence of vessels in between the @entity0 after usage of Vicryl and LigaClip when compared with electrothermic occlusion methods (p = 0.017). Histologic examination showed different courses of the inflammatory reaction and varying capillary counts. @entity2 methods do cause less vessel occurrence, less inflammatory reaction, and less histologic capillary formation. CONCLUSION: If a reconnection of the venous flow is desirable, the use of Vicryl and LigaClip might be superior to using electrothermic occlusion methods. In contrast, electrothermic methods cause less new vessel formation as well as less inflammatory reaction.

title: Surgical vein occlusion--comparison of four different methods in a XXXX model.

answer: @entity1


abstract: Invasive @entity4 is associated with frequent lymph node @entity1 and adverse clinical outcome. Initially described as a variant of @entity15 , it has subsequently been found in other organs, most recently the colon. Reports of @entity3 to date are limited in number, and their molecular profile has not been established. The aims of the present study were to analyze their clinicopathological features and molecular profile, and compare them with those of conventional @entity6 . Clinicopathological features of a cohort of 379 @entity0 with primary @entity3 were retrospectively reviewed for the presence of the pattern characteristic of @entity4 . We also assessed the expression of @entity16 , @entity11 , @entity18 , @entity12 (EMA, clone E29), @entity12 (clone MA695), @entity17 , @entity13 , @entity14 and @entity8 by immunohistochemistry. Genetic assessments of microsatellite instability, chromosomes 17p and 18q, and mutations in @entity8 , @entity7 and @entity10 were performed using DNA extracted from @entity5 -fixed, @entity9 -embedded sections. In all, 60 of the reviewed cases (16%) had a micropapillary component that ranged from 5 to 95% of the @entity2 , characterized by a higher frequency of an infiltrative pattern, lymphovascular and perineural invasion, a higher depth of invasion and more positive lymph nodes than conventional @entity6 . Immunohistochemistry for @entity12 (clone MA695) and @entity12 (EMA, clone E29) enhanced the characteristic inside-out staining pattern of the @entity4 component, whereas the rest of the @entity2 showed luminal staining patterns. @entity16 expression was slightly increased in @entity4 , but did not reach significance (17-3%, P=0.1967). The molecular parameters showed a higher frequency of @entity8 alterations and a low incidence of microsatellite instability and RER phenotype (loss of mismatch repair protein) in @entity4 . With regard to the histological parameters, @entity4 appears to be more aggressive than conventional @entity3 . The molecular profile supports the hypothesis that @entity4 carcinogenesis develops through the classical chromosomal instability pathway.

title: Clinicopathological and molecular characterization of XXXX .

answer: @entity3


abstract: BACKGROUND: @entity4 ( @entity4 ) is one of the most common @entity1 associated with @entity2 ( @entity2 ) correction. OBJECTIVE: To describe our MRI protocol for evaluating acquired @entity4 following @entity2 surgery, and associated imaging findings. MATERIALS AND METHODS: Two radiologists retrospectively reviewed 61 pelvic MRI examinations performed for postoperative @entity2 for @entity4 identification and characteristics. Associated clinical, operative and cystoscopy reports were also reviewed and compared to MRI. RESULTS: An abnormal retrourethral focus suspicious for @entity4 was identified at MRI in 13 @entity0 . Ten of these @entity0 underwent subsequent surgery or cystoscopy, and @entity4 was confirmed in five. All of the confirmed @entity4 cases appeared as @entity3 that were at least 1 cm in diameter in two imaging planes. Four of the false-positive cases were punctate retrourethral foci that were visible only on a single MRI plane. One @entity0 had a seminal vesical cyst mimicking a @entity4 . CONCLUSION: Pelvic MRI can be a useful tool in the postoperative assessment of suspected @entity4 associated with @entity2 . Radiologists should have a high clinical suspicion for a postoperative @entity4 when a cystic lesion posterior to the bladder/posterior urethra is encountered on two imaging planes in these @entity0 .

title: MRI of acquired posterior urethral diverticulum following surgery for XXXX .

answer: @entity2


abstract: INTRODUCTION AND OBJECTIVES: The aim of this study was to analyze the prevalence of principal cardiovascular risk factors in the female population from Biscay (northern Spain). @entity0 AND METHOD: We selected a random representative sample of 1,317 @entity0 aged between 16 and 65 years from this province. For each @entity0 we recorded the following parameters: weight and height, physical activity, smoking, blood pressure, glycemia, total @entity2 , @entity4 , HDL- @entity2 and LDL- @entity2 . RESULTS: A total of 1,100 @entity0 (mean age 39.83 14 years) participated. Regarding physical activity, 31.9% of the @entity0 had a sedentary lifestyle and 48.4% did not exercise during leisure time. The prevalence of smoking was 31.9%. We found a mean body mass index of 24.9 4.6 kg/m2, and 42.4% of the @entity0 were overweight. The prevalence of @entity1 was 13.1%, @entity1 being defined as a mean systolic blood pressure > or = 160 mmHg, diastolic blood pressure > or = 95 mmHg, current antihypertensive treatment, or any combination of these criteria. When a cutoff value of > or = 140/90 mmHg was used, the prevalence increased to 26.7%. Total @entity2 values were > or = 240 mg/dl in 26.2%, @entity3 levels were > or = 200 mg/dl in 2.6%, LDL- @entity2 was > or = 160 mg/dl in 26.8%, and HDL- @entity2 values were < 45 mg/dl in 12.2%. The prevalence of @entity5 was 3.3%. CONCLUSIONS: The prevalences of main cardiovascular risk factors were similar to those in other Spanish studies. Except for smoking, the rest of these risk factors increased with age. Long-term measures should be adopted to modify dietary habits and lifestyles to obtain improvements in the cardiovascular risk profile.

title: [Prevalence of main cardiovascular risk factors in XXXX from Biscay].

answer: @entity0


abstract: BACKGROUND: The impact of @entity2 remains controversial in @entity4 ( @entity4 ). STUDY DESIGN: One surgeon treated 159 unselected @entity0 , who were followed up for 1 to 27 years. We present a retrospective analysis with respect to @entity2 . @entity2 was investigated, including metachronous @entity2 (mpN(1)) in primarily node negative @entity0 (pN(0), clinical [c]N(0)). RESULTS: Therapeutic lymphadenectomies, prophylactic lymphadenectomies, or no lymphadenectomy were carried out in 42 ( @entity6 ), 29 (cN(0)), and 88 (cN(0)) @entity0 , respectively, with stage pN(1) in 41 (98%), in 5 (17%), and in 2 (2.3%) @entity0 , respectively (17% versus 2.3% p < 0.005). Sensitivity and specificity of clinical staging were 85% and 99%, respectively. More frequent prophylactic lymphadenectomy during the study period (p = 0.002) led to a nonsignificant increase in stage pN(1) (26% versus 30%). Immunohistochemistry led to upstaging of only 3% of histologically negative nodes and one (4%) pN(0) @entity0 . Nodal recurrence occurred in 8 of 156 @entity0 (5%) treated for cure, in 12% of pN(1) versus 3% of pN(0) cN(0) @entity1 (p = 0.009), in 15% of @entity3 high-versus 3% of low-risk @entity0 (p = 0.006), and in 5% each of @entity0 , younger than 45 and 45 years or more. In @entity3 high-risk @entity0 , @entity1 -related survival was 50% for stage pN(1) versus 86% for stage pN(0), cN(0) (p = 0.03) (100% and 100% in low-risk @entity0 ). CONCLUSIONS: The rate of occult @entity2 might be relatively low, and it does not frequently progress to clinical recurrent disease. Clinical nodal status might be valid for deciding the extent and radicality of node dissection. Prophylactic (central) lymphadenectomy should be carried out without radicality-associated morbidity. Macroscopic @entity2 warrants more rigorous, compartment-oriented lymphadenectomy. There is no rationale for detection of occult disease and @entity5 by frozen section or immunohistochemistry.

title: Lymph node surgery in XXXX .

answer: @entity4


abstract: UNASSIGNED: Background   To examine the results of myectomy and mitral valve surgery for systolic anterior motion (SAM) of the mitral valve and @entity3 ( @entity3 ) with a relatively thin interventricular septum. Methods   The subjects were 12 @entity0 with SAM and @entity3 . Eight had @entity2 ( @entity2 ) with a mean interventricular septal thickness of 16 mm. Three had sigmoid septum and one had an unknown etiology. For @entity2 , isolated extended myectomy was performed when @entity1 was mild (n   =   1) and extended myectomy plus mitral valve surgery was performed when @entity1 was more than mild (n   =   4) or primary valve etiologies existed (n   =   3). Myectomy was performed for the three cases with sigmoid septum. Myectomy plus height reduction of the posterior mitral leaflet was performed for the one case with the unknown etiology of SAM. Results   In the @entity0 with @entity2 , the maximum LVOT pressure gradient significantly decreased from 140        18 to 16        6 and 3        3   mm Hg, while @entity1 significantly decreased from 2.3        0.5 to 0.5        0.3 and 0.4        0.2 at pre-op, early post-op, and last follow-up (3        1 years), respectively. In the other etiologies, the maximum LVOT pressure gradient changed from 56        15 to 25        15 and 5        4   mm Hg; @entity1 changed from 2.0        0.6 to 1.3        0.3 and 1.3        0.8, at pre-op, early post-op, and the last follow-up (3        2 years), respectively. Conclusion   Myectomy with mitral valve surgery is an option for SAM and @entity3 in @entity0 with a relatively thin interventricular septum.

title: Surgery for Left XXXX with a Relatively Thin Interventricular Septum.

answer: @entity3


abstract: OBJECTIVE: The recent introduction of high-efficiency solid-state gamma cameras for myocardial perfusion single photon emission computed tomography has enabled lower @entity0 radiation dose, faster imaging, and improved image quality. However, artifacts still complicate interpretation. Prone imaging is a common maneuver to reduce artifacts and increase accuracy for detection of @entity1 , but its effect on imaging relative to supine imaging has not been fully characterized in these new systems. METHODS: In this IRB-approved, HIPAA-compliant retrospective study, 30 @entity0 were reviewed, who underwent prone and supine imaging on the GE 530c multipinhole @entity3 camera under both rest and stress conditions. Informed consent was waived. Perfusion was scored visually by two readers on a five-point scale according to the 17-segment model. Differences were assessed for significance using a multivariate linear effects model and restricted maximum likelihood method. RESULTS: Prone positioning resulted in increased activity in the basal inferior (P<0.001), basal inferolateral (P=0.009), basal inferoseptal (P<0.001), and mid-inferior (P<0.001) segments when taking into account factors such as stress versus rest, perfusion scores of other segments, and reader. CONCLUSION: Prone imaging on the GE 530c camera increases measured tracer activity in the basal inferior, basal inferolateral, basal inferoseptal, and mid-inferior segments. Caution is advised when diagnosing @entity2 in these territories, particularly if clinical data are unavailable.

title: Difference in appearance between prone and supine myocardial perfusion images obtained on a high-efficiency XXXX SPECT camera.

answer: @entity3


abstract: OBJECTIVES: The goals of this study were to perform a comprehensive assessment of the prevalence of @entity4 oncogene mutations in @entity2 of various histologic subtypes, and for any subgroup(s) in which @entity4 mutation was found to be common, to address the hypothesis that those @entity1 without @entity4 mutation had sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene. METHODS: A total of 104 primary, @entity2 from a 10-year period at this institution were selected for study based on histologic classification. The histologic cell type was serous in 21 cases, endometrioid in 30 cases, clear cell in 31 cases, and mucinous in 22 cases. Additional clinical and pathological information was abstracted from @entity0 records, and pathology review was performed for all cases. Direct sequence analysis of exon 2 of the @entity4 gene, containing codon 12, was performed using DNA isolated from all @entity1 specimens. Sequence analyses of exons 11 and 15 of the @entity3 gene were performed for the 22 cases of mucinous @entity2 . RESULTS: Activating @entity4 mutations were more common in @entity1 (50%) than in all other histologic types combined (5%; P < 10(-7)). Mutation of @entity4 was more common in @entity1 than in advanced stage @entity1 (P = 0.0004). Of the 11 @entity1 with @entity4 mutations, 6 were of Mullerian (endocervical) type and 5 were of gastrointestinal type. No @entity1 was found to harbor a @entity3 mutation. CONCLUSIONS: These data indicate that @entity4 oncogene mutations exist in several histologic types of @entity2 , especially @entity1 , but are common only in @entity1 of mucinous histology. Mutations are equally prevalent in mucinous @entity2 of M  llerian and gastrointestinal types. In contrast to other solid @entity1 types frequently affected by @entity4 mutation, mucinous @entity2 without a @entity4 mutation have not sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene.

title: Role of XXXX and @entity3 gene mutations in mucinous @entity2 .

answer: @entity4


abstract: OBJECTIVES: The goals of this study were to perform a comprehensive assessment of the prevalence of @entity4 oncogene mutations in @entity2 of various histologic subtypes, and for any subgroup(s) in which @entity4 mutation was found to be common, to address the hypothesis that those @entity1 without @entity4 mutation had sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene. METHODS: A total of 104 primary, @entity2 from a 10-year period at this institution were selected for study based on histologic classification. The histologic cell type was serous in 21 cases, endometrioid in 30 cases, clear cell in 31 cases, and mucinous in 22 cases. Additional clinical and pathological information was abstracted from @entity0 records, and pathology review was performed for all cases. Direct sequence analysis of exon 2 of the @entity4 gene, containing codon 12, was performed using DNA isolated from all @entity1 specimens. Sequence analyses of exons 11 and 15 of the @entity3 gene were performed for the 22 cases of mucinous @entity2 . RESULTS: Activating @entity4 mutations were more common in @entity1 (50%) than in all other histologic types combined (5%; P < 10(-7)). Mutation of @entity4 was more common in @entity1 than in advanced stage @entity1 (P = 0.0004). Of the 11 @entity1 with @entity4 mutations, 6 were of Mullerian (endocervical) type and 5 were of gastrointestinal type. No @entity1 was found to harbor a @entity3 mutation. CONCLUSIONS: These data indicate that @entity4 oncogene mutations exist in several histologic types of @entity2 , especially @entity1 , but are common only in @entity1 of mucinous histology. Mutations are equally prevalent in mucinous @entity2 of M  llerian and gastrointestinal types. In contrast to other solid @entity1 types frequently affected by @entity4 mutation, mucinous @entity2 without a @entity4 mutation have not sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene.

title: Role of @entity4 and XXXX gene mutations in mucinous @entity2 .

answer: @entity3


abstract: OBJECTIVES: The goals of this study were to perform a comprehensive assessment of the prevalence of @entity4 oncogene mutations in @entity2 of various histologic subtypes, and for any subgroup(s) in which @entity4 mutation was found to be common, to address the hypothesis that those @entity1 without @entity4 mutation had sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene. METHODS: A total of 104 primary, @entity2 from a 10-year period at this institution were selected for study based on histologic classification. The histologic cell type was serous in 21 cases, endometrioid in 30 cases, clear cell in 31 cases, and mucinous in 22 cases. Additional clinical and pathological information was abstracted from @entity0 records, and pathology review was performed for all cases. Direct sequence analysis of exon 2 of the @entity4 gene, containing codon 12, was performed using DNA isolated from all @entity1 specimens. Sequence analyses of exons 11 and 15 of the @entity3 gene were performed for the 22 cases of mucinous @entity2 . RESULTS: Activating @entity4 mutations were more common in @entity1 (50%) than in all other histologic types combined (5%; P < 10(-7)). Mutation of @entity4 was more common in @entity1 than in advanced stage @entity1 (P = 0.0004). Of the 11 @entity1 with @entity4 mutations, 6 were of Mullerian (endocervical) type and 5 were of gastrointestinal type. No @entity1 was found to harbor a @entity3 mutation. CONCLUSIONS: These data indicate that @entity4 oncogene mutations exist in several histologic types of @entity2 , especially @entity1 , but are common only in @entity1 of mucinous histology. Mutations are equally prevalent in mucinous @entity2 of M  llerian and gastrointestinal types. In contrast to other solid @entity1 types frequently affected by @entity4 mutation, mucinous @entity2 without a @entity4 mutation have not sustained alternative activation of this signaling pathway through mutation of the @entity3 oncogene.

title: Role of @entity4 and @entity3 gene mutations in mucinous XXXX .

answer: @entity2


abstract: BACKGROUND: Gating of sensory evoked potentials (SEPs) around the onset of a @entity1 is a physiological phenomenon with centripetal and central components, and may reflect sensorimotor integration required for normal movement control. OBJECTIVE: Our objective was the investigation of SEP suppression at the onset of movement and the interaction between SEP suppression and vibration of the limb. METHODS: Fourteen @entity0 with primary focal @entity2 and 17 age-matched healthy volunteers were studied. SEPs were elicited after electrical stimulation of the median nerve at the wrist. Electroencephalograms (EEGs) were recorded over the scalp at three sites according to the International 10-20 System (F3, @entity4 ). SEPs were recorded in four conditions: at rest, at the onset of movement (a self-paced abduction movement of the right thumb), both in the absence and in the presence of vibration of the limb. RESULTS: Repeated measures anova revealed that there was a significant main effect of group [F(1, 11.1) = 0.471, P = 0.002]. Post hoc exploration of this effect revealed it to be due to an absence of SEP suppression at movement onset in @entity0 (mean ratio SEP movement onset/rest 1.15 at F3, 1.13 at C3, 1.01 at P3) compared to controls, who had SEP suppression at movement onset (mean ratio SEP movement onset/rest 0.79 at F3, 0.78 at C3, 0.77 at P3). With vibration, SEP suppression reduced in both @entity0 and controls to a similar extent. CONCLUSION: These results demonstrate abnormal SEP suppression at the onset of movement in @entity0 with @entity3 , and in addition that vibration of the limb reduces SEP suppression in @entity0 and controls.

title: Abnormal movement-related suppression of sensory evoked potentials in XXXX .

answer: @entity2


abstract: OBJECTIVE: The purpose of this study was to describe the characteristics and outcome of @entity1 with metastatic @entity0 to the abdomen and pelvis, and to assess the role of surgical resection of abdominal and pelvic @entity2 in this disease. METHODS: We retrospectively reviewed the medical records of 59 @entity1 with documented metastatic @entity0 to the abdomen or pelvis who had exploratory surgery by the Gynecology Service between 1986 and 2001. RESULTS: Exploratory surgery was performed a median of 5 years (range, 0-25 years) after initial diagnosis of @entity0 . Median survival from diagnosis of @entity4 was 23 months, and 5-year survival was 24%. Survival was 36 months for optimally debulked @entity1 (<2 cm of @entity3 ) and 20 months for suboptimally debulked @entity1 (P = 0.07). @entity1 diagnosed 5 or more years after initial @entity0 had a median survival of 36 months versus 17 months if diagnosed earlier (P < 0.01). On multivariate analysis the time to recurrence of @entity0 in the abdomen and optimal debulking were both significant variables. Hazard ratio for dying of disease if recurring before 5 years was 2.7 (CI 1.45-5.03) [P < 0.01]. Hazard ratio for dying of disease if suboptimal debulking was achieved was 2.14 (CI 1.13-4.02) [P = 0.02]. CONCLUSIONS: The disease pattern of metastatic @entity0 to the abdomen and pelvis does not appear to effect survival. Survival in @entity1 where optimal debulking is achieved and in those recurring late is improved. Surgical resection of metachronous metastatic @entity0 to the abdomen and pelvis may be an important component of the management of this disease and should be considered in candidate @entity1 .

title: XXXX metastatic to abdomen and pelvis: role of surgical resection.

answer: @entity0


abstract: OBJECTIVES: To evaluate the sensitivity and specificity of serum tissue polypeptide antigen ( @entity3 ) as a @entity1 marker for monitoring @entity1 recurrence in a prospective Phase II study. METHODS: This study consisted of 421 subjects allocated to three groups: 241 @entity0 treated for @entity2 between 1991 and 1995, 126 subjects with a previous history of @entity2 but with no recurrence at the time of study enrollment, and 54 healthy volunteers. Soluble @entity3 concentrations were measured by radioimmunoassay. RESULTS: On the basis of receiver operating characteristic plot analysis, the normal test threshold was set at 63 U/L. For @entity2 detection, the @entity3 specificity was 73% and sensitivity was 45%. @entity3 levels correlated with @entity1 stage (P <0.01), histologic grade, nodal stage, and metastatic stage and with urinary cytology in univariate analysis. In the subsets of @entity0 with a history of @entity2 and normal @entity3 levels, 34.9% experienced a relapse compared with 37.5% of @entity0 with elevated @entity3 levels (no statistically significant difference). Among the @entity0 with normal @entity3 levels who experienced recurrence, the mean disease-free interval was 30.6 months compared with 25.1 months in @entity0 with elevated @entity3 levels (no statistically significant difference). Multivariate analysis showed that @entity3 was not an independent prognostic biomarker for @entity1 relapse. CONCLUSIONS: In @entity0 with @entity2 , the @entity3 serum level correlated with @entity1 stage and grade, but it was not useful for detecting or monitoring relapses.

title: Usefulness of tissue polypeptide antigen in the follow-up of XXXX .

answer: @entity2


abstract: OBJECTIVE: We describe in this first series of lupus documented in @entity10 , the epidemiological, diagnostic, therapeutic and prognostic aspects. METHOD: This is a prospective study in internal medicine at the National Hospital of Niamey during 10 years. ACR criteria were used as diagnostic criteria. RESULTS: We identified only 9 cases with a frequency of 0.05 % (7 @entity0 , 2 @entity0 ) with a mean age of 36.7 years [range, (26, 48)]. Frequent manifestations were prolonged fever (8 cases), @entity8 (6 cases), @entity5 (6 cases), @entity7 (5 cases), discoid lupus (3 cases), @entity1 (7 cases), @entity12 (4 cases) and @entity2 (4 cases). All @entity0 had at least 4 ACR criteria with an average of 6.11 criteria. ANA were positive in 8 @entity0 with an average of 1/568, 68 [extremes (1/1280-1/160)]. The most commonly molecules used were @entity3 , @entity4 and @entity11 . The Mycof  nolate Mof  til, @entity6 and @entity9 were used in a single @entity0 . The outcome was favorable in 8 @entity0 and we deplore the death of one @entity0 . CONCLUSION: Under diagnosis would be the basis of the low prevalence of lupus in @entity10 . Diagnostic means are necessary for epidemiological studies in order to have more representative data.

title: First documented cases of systemic lupus erythematosus in XXXX .

answer: @entity10


abstract: OBJECTIVES: To use the Bst U I polymorphism as a genetic marker in the search for the association between @entity0 with @entity3 and normal control subjects. The formation or progression of @entity3 is presumed to be associated with a polymorphism of the @entity2 ( @entity2 ) gene. The most frequently seen polymorphism is Bst U I (C to T) located at the -460th @entity4 upstream of the @entity2 gene. METHODS: A normal control group of 119 healthy @entity0 and 96 @entity0 with @entity3 were examined. The polymorphism was seen after polymerase chain reaction-based restriction analysis. RESULTS: The analysis revealed significant differences between normal individuals and @entity0 with @entity1 (P <0.001). Also, the distribution of the "TT" homozygote in the @entity0 group was greater than that in the control group. The odds ratio per copy of the "T" allele was 2.3 (95% confidence interval 1.4 to 3.8) and was 2.2 (95% CI 1.3 to 3.8) when adjusted for age. No statistically significant differences in clinical stage or grade were found. We also categorized the 54 @entity0 who received hormonal therapy into response and nonresponse groups, but no statistically significant differences between these two groups were revealed (P = 0.110, Fisher's exact test). CONCLUSIONS: The Bst U I polymorphism of the @entity2 gene is a suitable genetic marker of @entity3 but cannot be used in the prediction of the outcome of @entity0 who have received hormonal therapy.

title: XXXX gene-460 C/T polymorphism is a biomarker for @entity3 .

answer: @entity2


abstract: OBJECTIVES: To use the Bst U I polymorphism as a genetic marker in the search for the association between @entity0 with @entity3 and normal control subjects. The formation or progression of @entity3 is presumed to be associated with a polymorphism of the @entity2 ( @entity2 ) gene. The most frequently seen polymorphism is Bst U I (C to T) located at the -460th @entity4 upstream of the @entity2 gene. METHODS: A normal control group of 119 healthy @entity0 and 96 @entity0 with @entity3 were examined. The polymorphism was seen after polymerase chain reaction-based restriction analysis. RESULTS: The analysis revealed significant differences between normal individuals and @entity0 with @entity1 (P <0.001). Also, the distribution of the "TT" homozygote in the @entity0 group was greater than that in the control group. The odds ratio per copy of the "T" allele was 2.3 (95% confidence interval 1.4 to 3.8) and was 2.2 (95% CI 1.3 to 3.8) when adjusted for age. No statistically significant differences in clinical stage or grade were found. We also categorized the 54 @entity0 who received hormonal therapy into response and nonresponse groups, but no statistically significant differences between these two groups were revealed (P = 0.110, Fisher's exact test). CONCLUSIONS: The Bst U I polymorphism of the @entity2 gene is a suitable genetic marker of @entity3 but cannot be used in the prediction of the outcome of @entity0 who have received hormonal therapy.

title: @entity2 gene-460 C/T polymorphism is a biomarker for XXXX .

answer: @entity3


abstract: The prediction of chemotherapeutic efficacy is complicated by "protocol dependencies" in dose-effect and dose- @entity1 relationships. It has been proposed that pharmacokinetic-pharmacodynamic mathematical models may allow characterization of chemotherapeutic protocol dependencies, and may facilitate the prediction of chemotherapeutic efficacy; however, few demonstrations exist in the literature. The present study examines the pharmacokinetics and toxicodynamics of @entity2 ( @entity3 ), a commonly used anticancer agent, after intraperitoneal (i.p.) administration to @entity0 . @entity3 was administered via bolus or infusion (24, 72, and 168 h), at doses of 2.5-1000 mg/kg. @entity3 plasma and peritoneal pharmacokinetics were characterized through standard noncompartmental and compartmental techniques. Body weight loss was used as a measure of @entity3 -induced @entity1 . We found that @entity3 pharmacokinetics were independent of dose (over a range of 3-600 mg/kg) and independent of dosing mode (i.e., i.p. bolus vs. i.p. infusion). However, @entity3 -induced @entity1 was shown to be highly dependent on the dosing protocol used. For example, the maximally tolerated dose (i.e., the dose related to a mean body weight loss of 10%) was 200-fold greater after bolus administration relative to that observed for 72-h infusion (760 mg/kg vs. 3.8 mg/kg). This profound protocol dependence in the relationship between @entity3 -induced @entity1 and @entity3 exposure was characterized through the use of a time-dissociated pharmacokinetic-pharmacodynamic model (median prediction error: 3.9%).

title: Pharmacokinetic-pharmacodynamic modeling of @entity2 -induced XXXX in @entity0 .

answer: @entity1


abstract: The prediction of chemotherapeutic efficacy is complicated by "protocol dependencies" in dose-effect and dose- @entity1 relationships. It has been proposed that pharmacokinetic-pharmacodynamic mathematical models may allow characterization of chemotherapeutic protocol dependencies, and may facilitate the prediction of chemotherapeutic efficacy; however, few demonstrations exist in the literature. The present study examines the pharmacokinetics and toxicodynamics of @entity2 ( @entity3 ), a commonly used anticancer agent, after intraperitoneal (i.p.) administration to @entity0 . @entity3 was administered via bolus or infusion (24, 72, and 168 h), at doses of 2.5-1000 mg/kg. @entity3 plasma and peritoneal pharmacokinetics were characterized through standard noncompartmental and compartmental techniques. Body weight loss was used as a measure of @entity3 -induced @entity1 . We found that @entity3 pharmacokinetics were independent of dose (over a range of 3-600 mg/kg) and independent of dosing mode (i.e., i.p. bolus vs. i.p. infusion). However, @entity3 -induced @entity1 was shown to be highly dependent on the dosing protocol used. For example, the maximally tolerated dose (i.e., the dose related to a mean body weight loss of 10%) was 200-fold greater after bolus administration relative to that observed for 72-h infusion (760 mg/kg vs. 3.8 mg/kg). This profound protocol dependence in the relationship between @entity3 -induced @entity1 and @entity3 exposure was characterized through the use of a time-dissociated pharmacokinetic-pharmacodynamic model (median prediction error: 3.9%).

title: Pharmacokinetic-pharmacodynamic modeling of XXXX -induced @entity1 in @entity0 .

answer: @entity2


abstract: The prediction of chemotherapeutic efficacy is complicated by "protocol dependencies" in dose-effect and dose- @entity1 relationships. It has been proposed that pharmacokinetic-pharmacodynamic mathematical models may allow characterization of chemotherapeutic protocol dependencies, and may facilitate the prediction of chemotherapeutic efficacy; however, few demonstrations exist in the literature. The present study examines the pharmacokinetics and toxicodynamics of @entity2 ( @entity3 ), a commonly used anticancer agent, after intraperitoneal (i.p.) administration to @entity0 . @entity3 was administered via bolus or infusion (24, 72, and 168 h), at doses of 2.5-1000 mg/kg. @entity3 plasma and peritoneal pharmacokinetics were characterized through standard noncompartmental and compartmental techniques. Body weight loss was used as a measure of @entity3 -induced @entity1 . We found that @entity3 pharmacokinetics were independent of dose (over a range of 3-600 mg/kg) and independent of dosing mode (i.e., i.p. bolus vs. i.p. infusion). However, @entity3 -induced @entity1 was shown to be highly dependent on the dosing protocol used. For example, the maximally tolerated dose (i.e., the dose related to a mean body weight loss of 10%) was 200-fold greater after bolus administration relative to that observed for 72-h infusion (760 mg/kg vs. 3.8 mg/kg). This profound protocol dependence in the relationship between @entity3 -induced @entity1 and @entity3 exposure was characterized through the use of a time-dissociated pharmacokinetic-pharmacodynamic model (median prediction error: 3.9%).

title: Pharmacokinetic-pharmacodynamic modeling of @entity2 -induced @entity1 in XXXX .

answer: @entity0


abstract: The objectives of this study were to evaluate the bioavailability of cogranulated and oven-dried @entity2 ( @entity5 ) and @entity4 ( @entity6 ), in comparison to a physical mixture, and to examine the effect of endogenous bile on the bioavailability of the drug. In vitro dissolution studies were performed using USP type 2 apparatus. The granules and physical mixture were administered perorally in a crossover fashion, to male @entity0 bile duct-nonligated @entity0 . The granules were also perorally administered to bile duct-ligated @entity0 . Blood samples were taken at different time intervals and the plasma analyzed for @entity5 . Dissolution of granules was faster than the physical mixture due to faster @entity5 - @entity6 complex formation in solution from the former than the latter. The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively). However, in bile duct-ligated @entity0 , lower C(max) and AUC(0-8) (15.9 microg/mL and 14.4 h x microg/mL, respectively) were obtained for the granules. Phase solubility study of @entity5 in an aqueous @entity6 solution in the presence of the @entity3 ( @entity1 ), showed an increase in the solubility of @entity5 . Moreover, the stability constant value for the @entity5 - @entity6 complex was also found to decrease as the @entity1 concentration increased. These results indicated that the enhancement in the bioavailability of @entity5 was due to faster in-solution complex formation, and micelllar solubilization by the @entity3 .

title: Enhanced bioavailability of process-induced fast-dissolving XXXX cogranulated with @entity4 .

answer: @entity2


abstract: The objectives of this study were to evaluate the bioavailability of cogranulated and oven-dried @entity2 ( @entity5 ) and @entity4 ( @entity6 ), in comparison to a physical mixture, and to examine the effect of endogenous bile on the bioavailability of the drug. In vitro dissolution studies were performed using USP type 2 apparatus. The granules and physical mixture were administered perorally in a crossover fashion, to male @entity0 bile duct-nonligated @entity0 . The granules were also perorally administered to bile duct-ligated @entity0 . Blood samples were taken at different time intervals and the plasma analyzed for @entity5 . Dissolution of granules was faster than the physical mixture due to faster @entity5 - @entity6 complex formation in solution from the former than the latter. The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively). However, in bile duct-ligated @entity0 , lower C(max) and AUC(0-8) (15.9 microg/mL and 14.4 h x microg/mL, respectively) were obtained for the granules. Phase solubility study of @entity5 in an aqueous @entity6 solution in the presence of the @entity3 ( @entity1 ), showed an increase in the solubility of @entity5 . Moreover, the stability constant value for the @entity5 - @entity6 complex was also found to decrease as the @entity1 concentration increased. These results indicated that the enhancement in the bioavailability of @entity5 was due to faster in-solution complex formation, and micelllar solubilization by the @entity3 .

title: Enhanced bioavailability of process-induced fast-dissolving @entity2 cogranulated with XXXX .

answer: @entity4


abstract: PURPOSE: @entity0 survivors on aromatase inhibitors (AI) often experience side effects of joint @entity2 , @entity3 , or achiness ( @entity5 ). This study presents findings from a qualitative study of survivors on an AI regarding their knowledge of potential joint @entity2 side effects and how both AI side effects and their management through moderate physical activity could be discussed during routine visits with their oncology provider. METHODS: Qualitative data from semi-structured interviews were content analyzed for emergent themes. Descriptive statistics summarize sample characteristics. RESULTS: Our sample included 36 survivors, mean age of 67 (range 46-87); 86  % Caucasian and 70  % had education beyond high school. AI experience are as follows: 64  % @entity6 / @entity6 , 48  % @entity4 /Femara, and 31  % @entity7 / @entity7 . @entity1 expressed interest in having more information about potential joint @entity2 side effects when the AI was prescribed so they could understand their joint symptoms when they appeared or intensified. They were relieved to learn that their joint symptoms were not unusual or "in their head." @entity1 would have been especially motivated to try walking as a way to manage their joint @entity2 if physical activity had been recommended by their oncologist. CONCLUSIONS: @entity0 survivors who are prescribed an AI as part of their adjuvant treatment want ongoing communication with their oncology provider about the potential for joint @entity2 side effects and how these symptoms may be managed through regular physical activity. The prescription of an AI presents a "teachable moment" for oncologists to recommend and encourage their @entity1 to engage in regular physical activity.

title: Aromatase inhibitor associated XXXX : the importance of oncology provider- @entity1 communication about side effects and potential management through physical activity.

answer: @entity5


abstract: PURPOSE: @entity0 survivors on aromatase inhibitors (AI) often experience side effects of joint @entity2 , @entity3 , or achiness ( @entity5 ). This study presents findings from a qualitative study of survivors on an AI regarding their knowledge of potential joint @entity2 side effects and how both AI side effects and their management through moderate physical activity could be discussed during routine visits with their oncology provider. METHODS: Qualitative data from semi-structured interviews were content analyzed for emergent themes. Descriptive statistics summarize sample characteristics. RESULTS: Our sample included 36 survivors, mean age of 67 (range 46-87); 86  % Caucasian and 70  % had education beyond high school. AI experience are as follows: 64  % @entity6 / @entity6 , 48  % @entity4 /Femara, and 31  % @entity7 / @entity7 . @entity1 expressed interest in having more information about potential joint @entity2 side effects when the AI was prescribed so they could understand their joint symptoms when they appeared or intensified. They were relieved to learn that their joint symptoms were not unusual or "in their head." @entity1 would have been especially motivated to try walking as a way to manage their joint @entity2 if physical activity had been recommended by their oncologist. CONCLUSIONS: @entity0 survivors who are prescribed an AI as part of their adjuvant treatment want ongoing communication with their oncology provider about the potential for joint @entity2 side effects and how these symptoms may be managed through regular physical activity. The prescription of an AI presents a "teachable moment" for oncologists to recommend and encourage their @entity1 to engage in regular physical activity.

title: Aromatase inhibitor associated @entity5 : the importance of oncology provider- XXXX communication about side effects and potential management through physical activity.

answer: @entity1


abstract: @entity2 is traditionally thought of as a disease of plasma cells. Evidence from studies using antiodiotype antibodies, however, suggests that malignant events may take place in a precursor lymphocyte perhaps as early as the pre-B cell. In this study, we present cytogenetic evidence to support the latter view. Peripheral blood was obtained from a @entity0 with @entity3 and @entity1 . Karyotypic analysis, using Giemsa banding techniques, showed an abnormal karyotype: 44,XY,-6,-8,-13,-16,-22,+mar1,+ mar2,+mar3,del(1)(p22,p32),11p+,13q+,14q+. A suspension culture was established and a plasma cell line was grown. It was characterized by transmission electron microscopy as having an eccentric nucleus, abundant cytoplasm, and extensive endoplasmic reticulum. A subculture of this line was subsequently grown that was characterized by transmission electron microscopy as a lymphoid cell with diminished quantity of cytoplasm without extensive endoplasmic reticulum. Karyotypic analysis of the smaller cell demonstrated a modal number of 88 chromosomes and was a tetraploid derivative of the first. Our study provides cytogenetic evidence that cells with a lymphocytic phenotype show karyotypic abnormalities seen in the malignant plasma cell of the same @entity0 , and thus, can be considered as evidence favoring the initiating cell of plasma cell @entity2 as being an early B lymphocyte.

title: Cytogenetic evidence that the malignant event in multiple XXXX occurs in a precursor lymphocyte.

answer: @entity2


abstract: PURPOSE: To assess MR imaging findings and clinical manifestations of @entity3 ( @entity3 ). MATERIALS AND METHODS: We retrospectively reviewed our experience with diffuse @entity3 from November 1994 to October 2001. MR imaging findings and clinical features were assessed. RESULTS: Twenty-two consecutive @entity0 with diffuse-type @entity3 (19 @entity0 and three @entity0 , age range 16-80 years [mean, 52 years]) were identified in a review of liver MR studies. This represented 13% of all @entity0 with @entity3 imaged during this time period. Diffuse @entity3 showed a permeative, infiltrative pattern with ill-defined borders and no evidence of convex margination in all cases. At least 50% of the liver volume was involved with @entity1 . @entity3 showed hypointensity in 15 @entity0 , mixed intensity in three, and isointensity in four on T1-weighted images; heterogeneous hyperintensity in 16 @entity0 ; and homogeneous hyperintensity in six on T2-weighted MR images. @entity3 showed patchy enhancement in 12 @entity0 , miliary enhancement in nine, and minimal enhancement in one on postcontrast early-phase images, and showed heterogeneous wash-out in all @entity0 on postcontrast late-phase images. Proximal portal venous @entity1 @entity5 was seen in all patients. Serum @entity4 ( @entity4 ) value was elevated (>10 ng/mL) in 14 of 18 @entity0 , and 13 showed a value greater than 500 ng/mL. The four @entity0 who did not have elevated @entity4 had @entity1 which were indistinguishable from those in @entity0 with elevated @entity4 ; they also did not have a distinctive clinical history. CONCLUSION: @entity3 was typically seen as an extensive, heterogeneous permeative @entity2 , with portal venous @entity1 @entity5 on MR images in all cases. Early enhancement, observed as patchy in 12 and miliary in nine of 22 @entity0 , was a distinctive imaging feature. Elevated serum @entity4 value was a common finding; however, 22% had normal values.

title: XXXX of diffuse type: MR imaging findings and clinical manifestations.

answer: @entity3


abstract: The development of the iliac bones and lower limbs are parallel processes depending on the normal ontogeny of the caudal blastema [O'Rahilly and M  ller, 1989; Opitz, 1993; Opitz et al., 2000]. We hypothesized that the pathogenetic mechanisms leading to fused lower limbs would in parallel displace the ilia caudally and medially and that the degree of this displacement might correlate with the severity of the iliac and lower @entity1 . Thus the purpose of the study was to test this hypothesis in a sample of 12 sirenomelic fetuses. The fetuses GA 16-39 weeks, spontaneously or therapeutically aborted, were radiographed in the frontal projection as part of a requested autopsy. From each radiograph, a line was drawn connecting the most cranial part or the two ilia. After that the distance was measured vertically between this line and the most cranial part of the first sacral vertebral body ( @entity0 ( @entity0 )). A second distance was measured horizontally between the most lateral part of the two iliae (bi-iliac distance (BD)). As a result, @entity0 correlates with the iliac/femur phenotype. Separate ilia and femora occur only in cases with normal @entity0 . Fused ilia or femora or both are seen only in fetuses with mildly increased @entity0 , whereas a single iliac bone and femur occur only in cases with greatly increased @entity0 . The increase of the @entity0 does not correlate with the severity of more distal limb involvement. There was a correlation between the @entity0 and the BD values; the higher the @entity0 , the shorter the BD. Based on these findings, we propose an extended classification of @entity2 to be tested by other researchers.

title: XXXX sequence according to the distance between the first sacral vertebra and the ilia.

answer: @entity2


abstract: @entity4 is a @entity7 of unknown origin characterized by the trend to spontaneous remission in the great number of the @entity0 . Some @entity0 require treatment with @entity3 , which have significant @entity1 . The aim of this study was to assess the prognostic role of many different parameters in the @entity0 with @entity4 . 162 @entity4 @entity0 were introduced to prospective study: 22 @entity0 were treated because of deterioration in lung function or serious ocular disease and 140 were observed without therapy for two years. We assessed the age, sex, symptoms, serum activity of @entity8 (SACE), hypercalcaemia, @entity9 , @entity5 and HRCT findings at the time of diagnosis. We analyzed the frequency of spontaneous remission of @entity4 in the untreated @entity0 . We investigated correlation between these parameters and remission. Statistical comparisons were made with chi-square test. We also applied the k nearest neighbor (k-NN) rule and the leave one out method adopted from the statistical pattern recognition theory. From many different parameters only acute symptoms ( @entity10 , @entity2 , @entity6 ) and serum activity of ACE might be helpful in predicting prognosis in the @entity0 with stage I of disease. The @entity0 's age at onset less than 36 years, the appearance of @entity10 and ground-glass opacities on HRCT scans portend an excellent prognosis in the @entity0 with stage II of disease.

title: [Prognostic value of some clinical, radiological, laboratory and functional parameters in XXXX ].

answer: @entity4


abstract: BACKGROUND: @entity3 in pregnancy (NVP) and @entity5 gravidarum (HG) have a significant impact on quality of life. Medication to relieve symptoms of NVP and HG are available but pregnant @entity0 and their caregivers have been concerned about the teratogenic effect, side effects and poor efficacy. The aim of this review was to investigate if there is any clinical evidence for the efficacy of acustimulation in the treatment of NVP or HG. METHODS: A systematic review of randomized controlled trials (RCTs), including both English and Chinese databases was conducted to assess the efficacy of various techniques of acustimulation for NVP and HG. The methodological quality of the studies was assessed using the Cochrane's risks of bias tool. Revised STRICTA (2010) criteria were used to appraise acustimulation procedures. Pooled relative risks (RRp) and @entity4 ( @entity4 ) with 95  % confidence intervals (CI) were calculated from the data provided by the investigators of the original trials. RESULTS: Twenty-nine trials including 3519 @entity0 met the inclusion criteria. Twenty trials could be included in statistical pooling. The overall effect of different acustimulation techniques shows a significant reduction for the combined outcome for NVP or HG in pregnancy as a dichotomous variable ( @entity6 .73, 95  % CI 1.43 to 2.08). Studies with continuous outcome measures for @entity1 , @entity2 and the combined outcome did not show any evidence for relieving symptoms of NVP and HG ( @entity4 -0.12, 95  % CI -0.35 to 0.12). CONCLUSIONS: Although there is some evidence for an effect of acustimulation on @entity1 and @entity2 or @entity5 in pregnancy, results are not conclusive. Future clinical trials with a rigorous design and large sample sizes should be conducted to evaluate the efficacy and safety of these interventions for NVP and HG.

title: Effect of acustimulation on @entity1 and XXXX and on @entity5 in pregnancy: a systematic review of Western and Chinese literature.

answer: @entity2


abstract: BACKGROUND: @entity3 in pregnancy (NVP) and @entity5 gravidarum (HG) have a significant impact on quality of life. Medication to relieve symptoms of NVP and HG are available but pregnant @entity0 and their caregivers have been concerned about the teratogenic effect, side effects and poor efficacy. The aim of this review was to investigate if there is any clinical evidence for the efficacy of acustimulation in the treatment of NVP or HG. METHODS: A systematic review of randomized controlled trials (RCTs), including both English and Chinese databases was conducted to assess the efficacy of various techniques of acustimulation for NVP and HG. The methodological quality of the studies was assessed using the Cochrane's risks of bias tool. Revised STRICTA (2010) criteria were used to appraise acustimulation procedures. Pooled relative risks (RRp) and @entity4 ( @entity4 ) with 95  % confidence intervals (CI) were calculated from the data provided by the investigators of the original trials. RESULTS: Twenty-nine trials including 3519 @entity0 met the inclusion criteria. Twenty trials could be included in statistical pooling. The overall effect of different acustimulation techniques shows a significant reduction for the combined outcome for NVP or HG in pregnancy as a dichotomous variable ( @entity6 .73, 95  % CI 1.43 to 2.08). Studies with continuous outcome measures for @entity1 , @entity2 and the combined outcome did not show any evidence for relieving symptoms of NVP and HG ( @entity4 -0.12, 95  % CI -0.35 to 0.12). CONCLUSIONS: Although there is some evidence for an effect of acustimulation on @entity1 and @entity2 or @entity5 in pregnancy, results are not conclusive. Future clinical trials with a rigorous design and large sample sizes should be conducted to evaluate the efficacy and safety of these interventions for NVP and HG.

title: Effect of acustimulation on XXXX and @entity2 and on @entity5 in pregnancy: a systematic review of Western and Chinese literature.

answer: @entity1


abstract: BACKGROUND: @entity3 in pregnancy (NVP) and @entity5 gravidarum (HG) have a significant impact on quality of life. Medication to relieve symptoms of NVP and HG are available but pregnant @entity0 and their caregivers have been concerned about the teratogenic effect, side effects and poor efficacy. The aim of this review was to investigate if there is any clinical evidence for the efficacy of acustimulation in the treatment of NVP or HG. METHODS: A systematic review of randomized controlled trials (RCTs), including both English and Chinese databases was conducted to assess the efficacy of various techniques of acustimulation for NVP and HG. The methodological quality of the studies was assessed using the Cochrane's risks of bias tool. Revised STRICTA (2010) criteria were used to appraise acustimulation procedures. Pooled relative risks (RRp) and @entity4 ( @entity4 ) with 95  % confidence intervals (CI) were calculated from the data provided by the investigators of the original trials. RESULTS: Twenty-nine trials including 3519 @entity0 met the inclusion criteria. Twenty trials could be included in statistical pooling. The overall effect of different acustimulation techniques shows a significant reduction for the combined outcome for NVP or HG in pregnancy as a dichotomous variable ( @entity6 .73, 95  % CI 1.43 to 2.08). Studies with continuous outcome measures for @entity1 , @entity2 and the combined outcome did not show any evidence for relieving symptoms of NVP and HG ( @entity4 -0.12, 95  % CI -0.35 to 0.12). CONCLUSIONS: Although there is some evidence for an effect of acustimulation on @entity1 and @entity2 or @entity5 in pregnancy, results are not conclusive. Future clinical trials with a rigorous design and large sample sizes should be conducted to evaluate the efficacy and safety of these interventions for NVP and HG.

title: Effect of acustimulation on @entity1 and @entity2 and on XXXX in pregnancy: a systematic review of Western and Chinese literature.

answer: @entity5


abstract: UNASSIGNED: The biosynthetic pathway for hyaluronic acid (HA) has been proposed; however, a thorough genetic and functional analysis is required to further elucidate the roles of genes involved in HA production. Previously, we developed a markerless gene-deletion system for @entity2 and confirmed that hasA is essential for HA synthesis. Here, we constructed a comprehensive set of deletion mutants and investigated the roles of ten additional predicted genes in the HA synthetic pathway. Phenotypic assays revealed that all ten genes play a role in cell growth and/or HA synthesis. As expected, the deletion of hasA or hasB abolished HA production with little effect on growth, while the deletion of genes that are also required for peptidoglycan biosynthesis (hasE, glmM, and glmS) significantly reduced cell growth and HA production. Either of the glmU homologues (hasD and gcaD) was sufficient for optimal growth and the mucoid phenotype, while no double mutant could be isolated. Of the two @entity1 - @entity0 pyrophosphorylase (UGPase) paralogues, the operon-encoded hasC1 was responsible for 65  % of the activity, while hasC2 was responsible for the remaining 35  %. The deletion of hasC1 had no effect on cell growth and caused only a moderate decrease in the @entity1 - @entity0 level and HA production. The deletion of both hasC1 and hasC2 resulted in a severe growth defect and negligible @entity1 - @entity0 accumulation, HA production, and pyrophosphorylase activity. Of the two phosphoglucomutase paralogues, pgm1 and pgm2, the former is responsible for around 10  % of activity, while the latter is responsible for 90  %. The deletion of pgm1 showed no apparent effect on HA synthesis and growth, while the deletion of pgm2 resulted in the abolishment of HA synthesis and a significantly slower growth. These results should guide the metabolic engineering of @entity2 to improve HA productivity and quality.

title: Genetic and biochemical characterization of genes involved in hyaluronic acid synthesis in XXXX .

answer: @entity2


abstract: Newer varieties of occupational @entity3 primarily due to the vast increase in industrial technology have been reported recently. Preeminent among such newer agents are @entity7 (VC) and @entity5 . Very few cases have been reported, in Europe only, with descriptive histopathologic changes. To our knowledge, no pathologic studies of VC exposure have been described in the American literature. The biopsy abnormalities in our @entity0 disclosed desquamation of alveolar macrophages into the alveolar lumina and minor interstitial and alveolar inflammatory changes. Pulmonary function abnormalities included @entity4 . Preventive therapy consists of the avoidance of further exposures, frequent industrial hygiene monitoring, and total avoidance of @entity2 smoke, as well as associated atmospheric pollutants. Thus far, none of these @entity0 has exhibited evidence of @entity1 . All three @entity0 survived their occupational injuries, and two are still disabled to varying degrees. Urine and blood levels of @entity6 derivatives were elevated in two @entity0 , the exact significance of which is not fully known. It probably represents a toxicologic response, but must be further pursued before conclusions can be reached.

title: Pulmonary manifestations of vinyl and XXXX (interstitial lung disease). Newer aspects.

answer: @entity5


abstract: For rehabilitation training it is recommended that the intensity of exercise should be clearly below the individual anaerobic threshold (IAT). We investigated @entity1 , particularly endogenous @entity0 potential (ETP) and fibrinolysis following a standardized treadmill (TR) ergometer test at 90% IAT for 60-120 min. Sixteen healthy male non-smokers underwent the TR test. Blood samples were taken after a 30-min rest, immediately after exercise, and 2 h after exercise completion. Extrinsic and intrinsic total ( @entity2 (ex+in)) and endogenous (ETP(ex+in)) @entity0 potential, prothrombin fragment 1+2 (F1+2), @entity0 -antithrombin complex (TAT), plasmin-alpha2-antiplasmin complex (PAP), D-dimer, tissue plasminogen activator antigen and activity (tPA-AG and tPA-ACT) and plasminogen activator inhibitor type 1 antigen and activity ( @entity3 -AG and @entity3 -ACT) were measured. Immediately after TR, F1+2, TAT and @entity2 (ex+in) were increased ( P<0.05) while ETP(ex+in) remained unchanged. In contrast, @entity4 , D-dimer, tPA-AG, tPA-ACT ( P<0.05) were distinctly enhanced while @entity3 -ACT was decreased ( P<0.05) immediately after exercise. The changes in tPA-AG, tPA-ACT, and @entity3 -ACT were reversed to nearly baseline while the enhancement in PAP and D-dimer was prolonged by more than 2 h after exercise. Long-duration exercise between 60 and 120 min controlled by IAT (90%) on a TR ergometer only implicates a small increase in @entity0 generation markers and total (free and alpha(2)-macroglubulin-bound @entity0 ), but not in endogenous (free) @entity0 potential alone. In contrast, fibrinolysis is distinctly increased after this type of exercise. Endurance exercise with an intensity below 90% IAT and a duration below 2 h generates a more favourable condition for fibrinolysis than for @entity1 in healthy young subjects. Data are given as mean (SD).

title: XXXX and fibrinolysis after long-duration treadmill exercise controlled by individual anaerobic threshold.

answer: @entity1


abstract: By means of a cytological technique involving @entity1 , @entity2 , and fluorescence microscopy, the asynchronously replicating, hence genetically inactivated, X chromosome was identified in 6- to 8-day embryos from female @entity0 heterozygous for Searle's translocation T(X;16)16H (abbreviated as @entity3 ) mated with either karyotypically normal males or males carrying Cattanach's translocation T(X;7)1Ct in order to analyse the way in which the total inactivation of the normal X is achieved in adult @entity3 heterozygotes. Embryos examined included 9 Xn/X(7);16/16, 3 X 16/Xn;16x/16, 12 @entity4 /X(7); 16x/16, 5 @entity4 /Xn;16/16, 8 @entity4 /X(7); 16/16 and 2 Xn/Y; 16x/16/16. In these notations @entity4 , 16x, X(7) and Xn represent Searle's X with the centromeric segment of the X, Searle's X with the centomeric segment of chromosome 16, Cattanach's X with insertion of a chromosome 7 segment, and normal X, respectively. The X(7) exerted no apparent effect upon embryonic development up to the 8th day of gestation and X chromosome inactivation. -- The asynchronously replicating X was the Xn in @entity4 /Xn;16x/16 and X(7) in @entity4 /X(7);16x/16 embryos except a small number of cells on day 6 (13/493) and on day 7 (1/886) in which almost the entire 16x replicated asynchronously. The @entity4 , on the other hand, never showed replication asynchrony. That the @entity4 is indeed unable to become inactivated was indicated by the observation that the @entity4 as well as Xn or X(7) did not replicate asynchronously in Xn/ @entity4 ;16/16 and @entity4 /X(7);16/16 embryos @entity4 -inactive cell lines, if occurring, should have been genetically less unbalanced than any other cell line in such embryos. It is highly likely therefore that the ultimate inactivation pattern in @entity3 heterozygotes has been accomplished by (1) the inability of the @entity4 to become inactive; (2) inactivation in favor of the Xn; and (3) rapid elimination of 16x-inactive cells. Severe growth retardatin and early death of @entity4 /Xn;16/16 and @entity4 /X(7);16/16 embryos having no inactive X suggested that functional X disomy is detrimental to embryogenesis. These embryos further indicated that the concurrence of at least two X chromosomal loci separated by the @entity3 breakpoint is necessary for the homologous X chromosome becoming inactivated.

title: Primary and secondary nonrandom X chromosome inactivation in early female XXXX embryos carrying Searle's translocation T(X; 16)16H.

answer: @entity0


abstract: AIM: Evaluation of effect on tolerance of topical pharyngeal anaesthesia with a @entity1 spray in esophagogastroduodenoscopy (EGD), and possible secondary factors that could influence it. METHODS: A prospective, experimental, randomized, open-label study was performed in our Endoscopy Unit during January 2010. Outpatients (109) were recruited prospectively and randomized between two groups: L group (52), who received @entity1 (50 mg Xilonibsa 10% before examination), and C group (57) who did not. Sedated @entity0 were not included in this study. Age, sex, Mallampati index (lower I and II; higher III and IV), endoscopist, complications and score (0-100; visual analogue scale) was recorded after each EGD. RESULTS: There were no statistical differences between the two groups as regards @entity0 tolerance. However in stratified analysis the application of @entity1 modified the results in two out of the six endoscopists and improved the scores in @entity0 with a higher Mallampati Index (L group 61.8    24 and C group 47.7    32). Significant differences were also observed in the scores on @entity0 tolerance between the endoscopist (operator dependent factor), regardless of the use of topical pharyngeal anaesthesia or not. CONCLUSIONS: The systematic use of @entity1 in EGD is safe but does not improve the tolerance in all outpatients. Only the Mallampati index has been identified as a prognosis factor of good response to @entity1 administration. Additionally the nursing-endoscopist could be a very important factor in the scores obtained independently of @entity1 .

title: [Use of topical pharyngeal anaesthesia in esophagogastroduodenoscopy in unsedated XXXX ].

answer: @entity0


abstract: Endoscopic electrocoagulation with a liquid monopolar probe was exclusively attempted in 77 @entity0 with major @entity1 from peptic @entity2 assessed as requiring emergency surgery. Endoscopy failed to control @entity1 in 14 @entity0 (18%), who proceeded directly to surgery. Initial endoscopic hemostasis was obtained in 63 @entity0 , but @entity1 recurred in 18 (29%). Rebleeding required surgery in 11 @entity0 and another @entity0 died prior to surgery. Permanent endoscopic control was achieved in 51 @entity0 (66%). Without difference in transfusion requirement, endoscopy was most likely to succeed in @entity0 with superficial acute @entity2 , onset of @entity1 in hospital, @entity4 , no earlier history of @entity3 and in @entity0 with previous @entity2 surgery. Endoscopy was less likely to succeed in @entity0 with @entity5 , though it controlled major @entity1 in more than half of such @entity0 . Profuse @entity1 , and in particular poor access in a narrowed duodenal bulb, were important determinants of endoscopic failure. Of the @entity0 with permanent endoscopic hemostasis, 8% subsequently underwent elective @entity2 surgery. Endoscopic electrocoagulation is safe and has potential to control major @entity1 , obviating emergency surgery, in two-thirds of the cases. As the less invasive method, endoscopy should be attempted before surgery, particularly in @entity0 regarded as poor surgical risks or with no history of @entity3 .

title: Endoscopic electrocoagulation of major @entity1 from peptic XXXX .

answer: @entity2


abstract: Endoscopic electrocoagulation with a liquid monopolar probe was exclusively attempted in 77 @entity0 with major @entity1 from peptic @entity2 assessed as requiring emergency surgery. Endoscopy failed to control @entity1 in 14 @entity0 (18%), who proceeded directly to surgery. Initial endoscopic hemostasis was obtained in 63 @entity0 , but @entity1 recurred in 18 (29%). Rebleeding required surgery in 11 @entity0 and another @entity0 died prior to surgery. Permanent endoscopic control was achieved in 51 @entity0 (66%). Without difference in transfusion requirement, endoscopy was most likely to succeed in @entity0 with superficial acute @entity2 , onset of @entity1 in hospital, @entity4 , no earlier history of @entity3 and in @entity0 with previous @entity2 surgery. Endoscopy was less likely to succeed in @entity0 with @entity5 , though it controlled major @entity1 in more than half of such @entity0 . Profuse @entity1 , and in particular poor access in a narrowed duodenal bulb, were important determinants of endoscopic failure. Of the @entity0 with permanent endoscopic hemostasis, 8% subsequently underwent elective @entity2 surgery. Endoscopic electrocoagulation is safe and has potential to control major @entity1 , obviating emergency surgery, in two-thirds of the cases. As the less invasive method, endoscopy should be attempted before surgery, particularly in @entity0 regarded as poor surgical risks or with no history of @entity3 .

title: Endoscopic electrocoagulation of major XXXX from peptic @entity2 .

answer: @entity1


abstract: Histochemical staining for three hydrolytic enzymes were performed in 35 @entity0 and 43 soft tissue @entity0 , malignant as well as benign. @entity2 , intra-osseous as well as extra-osseous, revealed characteristic rich staining for alkaline phosphatase, no matter how dedifferentiated the @entity0 was. Haemangioendothelioma (and normal endothelium), too, showed strong reaction for alkaline phosphatase whereas haemangiopericytoma did not. Alkaline phosphatase furthermore was found in slight to moderate amounts in fibrous proliferations. All other @entity0 examined were negative. Acid phosphatase was found in almost every @entity0 investigated except @entity6 and @entity1 . However, high activity was characteristic of @entity0 and @entity4 . The inhibition of acid phosphatase by tartrate was complete except in @entity2 and @entity0 , where only a partial inhibition was seen. There were non-specific esterase reactions in a variety of @entity0 , but very strong reactions were characteristic of @entity4 and @entity0 . The reaction could be completely inhibited by the addition of @entity3 . In an era of increasing application of immunohistologic techniques in surgical pathology it might be of value to remember that simple enzyme histochemical stainings may provide helpful diagnostic features in the classification of @entity5 .

title: Enzyme histochemical investigations on XXXX .

answer: @entity5


abstract: This study describes the results of @entity7 testing in 100 consecutive @entity0 who underwent this procedure in a coronary care unit. All @entity0 had recently undergone coronary arteriography. A bolus injection of @entity7 was administered at 5 minute intervals in the following doses (mg): 0.0125, 0.025, 0.05, 0.1, 0.2, 0.3 and 0.4. The criterion for a positive test was the appearance of S-T elevation greater than 1 mm. The test was positive in all 17 @entity0 known to have @entity8 and in 18 (40 percent) of 45 @entity0 who had a history of @entity4 judged strongly suggestive of @entity8 but who had no electrocardiogram recorded during @entity1 . Of 38 @entity0 with a history of @entity4 classified as not entirely typical of @entity8 , only 1 (2.6 percent) had a positive test. Of the 64 @entity0 with a negative @entity7 test, 47 had @entity4 and 25 had @entity2 but none had more serious complications. @entity5 accompanied S-T elevation in 18 of the 36 @entity0 with a positive test but occurred in only 4 of the 64 with a negative test (p < 0.0005). No @entity0 needed treatment with antiarrhythmic drugs. Four of the 36 @entity0 with a positive test had serious complications: severe transient @entity3 (2 @entity0 ), recurrent episodes of angina with S-T elevation (1 @entity0 ) and a @entity6 (1 @entity0 ). Thus, @entity7 testing is useful in @entity0 with a typical clinical history of @entity8 but without an electrocardiogram recorded during @entity1 . In this study, a small but definite incidence of serious complications occurred during a positive test.

title: XXXX testing in a coronary care unit.

answer: @entity7


abstract: An open study of @entity6 has been achieved in a @entity1 unit. The drug has been prescribed to 36 @entity0 , all comers, half of them aged 60. Out of them 28 are affected by a @entity3 , six by a @entity3 . In terms of the importance of the @entity3 signs, medium posologies (300 mg a day) or strong ones (600 mg a day) are used. The total result is excellent or good in 65% of the cases: it becomes evident in more than one case out of two during the first week. To get it the treatment must absolutely be extended and process to higher posologies may be necessary. @entity5 and the @entity3 phase of chronic @entity4 constitute the best terms of @entity6 . Hypnotics have to be associated but systematic prescription of @entity2 relieving is to be avoided. Tolerance is satisfactory in three cases out of four and the drug is free from the clinical counter-indications belonging to anti-depressants. This allows us to prescribe it to old age in high posologies without any harm.

title: [Clinical study of XXXX (author's transl)].

answer: @entity6


abstract: From a symptom-limited bicycle exercise test 3 wk after acute @entity1 is 205 @entity0 the prognostic significance for the 1-yr prognosis of the following variables was examined by a multivariate analysis (Cox's model): reasons for stopping, duration of work, maximal heart rate, maximal product heart rate x systolic blood pressure, maximal ST-deviation, time to maximal ST-deviation and @entity3 (type and frequency). The reason for stopping was fatigue in 59% and @entity2 in 15%. 48% exercised up to 6 min and 14% beyond 12 min with median duration of 7 min. The maximal heart rate was over 140/min in 30%. ST-deviations were found in 77%; in most @entity0 below 3 mm. 44% had @entity3 during the exercise. The only significant variable was the duration of of work with prognostic index for the 1-yr prognosis SE: SE = 1.21-0.16 x (duration of work). A probability of survival of over 0.95 after 1 yr required a duration of work over 13 min. The observed deaths were in good accordance with the expected with a little overestimation. 75% died from a definite cardial cause. There is a good predictive value for the 1-yr prognosis of the duration of work from an exercise test 3 wk after AMI.

title: Multivariate long-term prognostic index from exercise ECG after acute XXXX .

answer: @entity1


abstract: BACKGROUND: @entity4 is a disease well known to dermatologists because of the frequency of cutaneous involvement. Routine screening is performed for involvement of the lungs, lymph nodes, eyes, liver and heart. However, gastro-intestinal @entity4 is both rare and frequently silent, and it thus often goes undiagnosed. We report the case of a Caribbean @entity0 whose cutaneous lesions allowed a posteriori diagnosis to be made of @entity3 . @entity0 AND METHODS: A 45-year-old Caribbean @entity0 consulted for diffuse erythematous or @entity5 , squamous and follicular micropapular lesions associated with @entity2 . Clinical examination and laboratory data led to a diagnosis of @entity4 . It was later discovered that she had presented @entity1 a few months earlier and that she had undergone gastroscopy and gastric biopsies. Histopathology had revealed non-caseating epithelioid-cell granulomas with giant cells, but no further exams were performed. The @entity0 was diagnosed a posteriori with cutaneous-articular and @entity3 . DISCUSSION: In contrast with hepatic involvement, which is frequent and well-known, @entity4 affecting the gastro-intestinal tract is rare and poorly known. This form of the disease is frequently clinically silent and is thus probably under-reported. The stomach is the site most frequently affected. @entity3 is seen in some 10% of @entity0 with systemic @entity4 and is symptomatic in less than 1% of cases. It is important to diagnose these forms since they may be associated with a certain degree of morbidity.

title: [ @entity3 revealed by cutaneous follicular XXXX ].

answer: @entity4


abstract: BACKGROUND: @entity4 is a disease well known to dermatologists because of the frequency of cutaneous involvement. Routine screening is performed for involvement of the lungs, lymph nodes, eyes, liver and heart. However, gastro-intestinal @entity4 is both rare and frequently silent, and it thus often goes undiagnosed. We report the case of a Caribbean @entity0 whose cutaneous lesions allowed a posteriori diagnosis to be made of @entity3 . @entity0 AND METHODS: A 45-year-old Caribbean @entity0 consulted for diffuse erythematous or @entity5 , squamous and follicular micropapular lesions associated with @entity2 . Clinical examination and laboratory data led to a diagnosis of @entity4 . It was later discovered that she had presented @entity1 a few months earlier and that she had undergone gastroscopy and gastric biopsies. Histopathology had revealed non-caseating epithelioid-cell granulomas with giant cells, but no further exams were performed. The @entity0 was diagnosed a posteriori with cutaneous-articular and @entity3 . DISCUSSION: In contrast with hepatic involvement, which is frequent and well-known, @entity4 affecting the gastro-intestinal tract is rare and poorly known. This form of the disease is frequently clinically silent and is thus probably under-reported. The stomach is the site most frequently affected. @entity3 is seen in some 10% of @entity0 with systemic @entity4 and is symptomatic in less than 1% of cases. It is important to diagnose these forms since they may be associated with a certain degree of morbidity.

title: [ XXXX revealed by cutaneous follicular @entity4 ].

answer: @entity3


abstract: BACKGROUND: We have proposed that declines in adaptive capacity, defined as the ability to adapt to multiple stressors, may serve as an indicator of risk for @entity2 . A comprehensive measure of adaptive capacity does not exist. OBJECTIVES: In this paper we describe construction of an instrument to measure adaptive capacity, the Adaptive Capacity Index (ACI). DESIGN: Descriptive and psychometric. SETTING: Six sites providing palliative care in Western Canada. @entity0 :                 <AbstractText Label="INCLUSION CRITERIA" NlmCategory="METHODS">>= 18 years old, diagnosed with @entity1 , able to read and write English, Mini-Mental Status Exam score >= 22. Pilot study n=48; Main study n=225 stratified using the Edmonton Symptom Assessment Scale (ESAS) tiredness score (>= 0 to  <=2 n=60; >= 3 to  <=6 n=108; >= 7 and  <=10 n=57). METHODS: Following ethics approval, 17 experts in symptom management assisted with content validation and consenting individuals completed the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), the Profile of Mood States-Vigor short form (POMS-Vsf), and the ACI. A research assistant collected demographic information and assigned an Eastern Cooperative Oncology Group (ECOG) score. Data were analyzed using descriptive and inferential statistics (i.e., exploratory factor analyses, correlation, multivariate analyses of variance, and multiple regression). RESULTS: Five 6-item ACI factors/subscales (Cognitive Function, Stamina/Muscle Endurance, Sleep Quality, Emotional Reactivity, and Social Interaction) were identified. The ACI-total scale and its subscales were internally consistent (Cronbach's alpha 0.76-0.89), and were significantly correlated with each other, and with each @entity2 measure (Pearson's r ranging from -0.724 to 0.634). The ACI total score was sensitive to changes in the ESAS tiredness score. Stamina/Muscle Endurance, Cognitive Function, and Sleep Quality predicted 60.8% of the variance in FACT-F. Stamina/Muscle Endurance and Social Interaction predicted 36.8% of the variance in POMS-Vsf. Stamina/Muscle Endurance and Sleep Quality predicted 8% of the variance in ECOG. CONCLUSIONS: The ACI is reliable and has beginning evidence of validity. In future studies we will examine relationships between ACI subscale scores and subsequent increases in @entity2 and explore linkages to physiological processes. We will also establish ACI norms for early and late stage @entity1 and explore variations in ACI subscale scores base on age or gender.

title: Development and psychometric testing of the Adaptive Capacity Index, an instrument to measure adaptive capacity in individuals with XXXX .

answer: @entity1


abstract: INTRODUCTION: @entity2 ( @entity2 ) often starts in childhood or adolescence. There is considerable scepticism outside the United States over the validity, stability and prevalence of @entity2 in @entity0 and adolescents. Persistence of course lends support to the validity of a diagnosis. OBJECTIVES: To describe the longitudinal course of pediatric @entity2 in a Spanish sample over a median follow-up period of 2.6years and to examine risk factors associated with outcome. METHODS: We retrospectively reviewed the medical records of all @entity0 and adolescents (N=38) with DSM-IV-TR @entity2 -I, II and NOS evaluated in the @entity0 and Adolescent Psychiatry Unit, University of Navarra (Pamplona, Spain) from 1999 to 2005. We used the NIMH Lifetime Mood Chart and the Clinical Global Impression-Severity Scale to assess clinical course. RESULTS: 79% (N=30) were @entity0 and 21% (N=8) were @entity0 ; 44.7% (N=17) had @entity2 -I, 5.3% (N=2) @entity2 -II, and 50% (N=19) @entity2 -NOS. Median (inter-quartile range: IQR: Q25; Q75) age at diagnosis was 13.9 (10.64; 15.84). Median follow-up period was 2.6years (0.91; 3.66). Mean percentage of time in an episode was 46.17% (23.36; 75.26), and it was longer in younger @entity0 (p<0.05). 2.6% had rapid cycling. At the end of follow-up, only 47% achieved remission or recovery. Younger @entity0 showed a worse treatment response (p<0.05). We found higher rates of hospitalization in @entity0 with @entity1 (21%) (p<0.05). CONCLUSION: @entity0 with @entity2 had a chronic course with little interepisodic recovery. @entity2 can be diagnosed in @entity0 using DSM-IV-TR criteria. An early age of onset and @entity1 comorbidity are risk factors for worse prognosis.

title: XXXX in a Spanish sample: results after 2.6years of follow-up.

answer: @entity2


abstract: INTRODUCTION AND OBJECTIVES: @entity7 ( @entity7 ) after pelvic radiotherapy occurs in 2-8% of @entity0 . A variety of treatments have been described, most of them with uncertain results. We assessed the efficacy of hyperbaric @entity2 therapy (HBOT) in @entity7 cases. @entity0 AND METHODS: retrospective analysis of @entity0 with @entity7 after pelvic radiotherapy receiving HBOT at our center between January 2002 and January 2010. Our protocol included 40 sessions of HBOT in a multiplace hyperbaric chamber with 90minutes of 100% @entity2 breathing at 2.2 atm. Success was evaluated in terms of total or partial stop of @entity6 . Telephone follow-up was updated at the time of submission in all cases. RESULTS: twenty-five @entity0 were treated (21 male, 4 female); the mean age was 66.7 years. Twenty @entity0 were irradiated for @entity4 and one for @entity3 . Three @entity0 had @entity1 and one @entity5 . In all cases previous conservative treatment had failed and HBOT was considered only after other measures failed. All the @entity0 responded to HBOT and none recurred after end of treatment at a mean follow-up of 21.2 months. There were no serious complications. CONCLUSION: HBOT is a highly effective and safe, non-invasive therapy for @entity7 secondary to pelvic radiation; it should be considered as first line alternative in these difficult cases.

title: [Management of hemorrhagic @entity7 with hyperbaric XXXX therapy].

answer: @entity2


abstract: INTRODUCTION AND OBJECTIVES: @entity7 ( @entity7 ) after pelvic radiotherapy occurs in 2-8% of @entity0 . A variety of treatments have been described, most of them with uncertain results. We assessed the efficacy of hyperbaric @entity2 therapy (HBOT) in @entity7 cases. @entity0 AND METHODS: retrospective analysis of @entity0 with @entity7 after pelvic radiotherapy receiving HBOT at our center between January 2002 and January 2010. Our protocol included 40 sessions of HBOT in a multiplace hyperbaric chamber with 90minutes of 100% @entity2 breathing at 2.2 atm. Success was evaluated in terms of total or partial stop of @entity6 . Telephone follow-up was updated at the time of submission in all cases. RESULTS: twenty-five @entity0 were treated (21 male, 4 female); the mean age was 66.7 years. Twenty @entity0 were irradiated for @entity4 and one for @entity3 . Three @entity0 had @entity1 and one @entity5 . In all cases previous conservative treatment had failed and HBOT was considered only after other measures failed. All the @entity0 responded to HBOT and none recurred after end of treatment at a mean follow-up of 21.2 months. There were no serious complications. CONCLUSION: HBOT is a highly effective and safe, non-invasive therapy for @entity7 secondary to pelvic radiation; it should be considered as first line alternative in these difficult cases.

title: [Management of hemorrhagic XXXX with hyperbaric @entity2 therapy].

answer: @entity7


abstract: UNASSIGNED: Bore morphogenetic proteins (BMPs) are members of the transforming growth factor (TGF)-b superfamily, a group of secreted proteins that regulate embryonic development. This review summarizes the effects of BMPs on physiological processes not exclusively linked to the musculoskeletal system. Specifically, we focus on the involvement of BMPs in inflammatory disorders, e.g. @entity4 , @entity2 , @entity9 , @entity5 . Moreover, we discuss the role of BMPs in the context of @entity8 , and explore the role of these signalling proteins in @entity3 homeostasis ( @entity7 , @entity11 ) and oxidative damage. The second and third parts of this review focus on BMPs in the development of metabolic pathologies such as @entity0 and @entity1 . The pancreatic beta cells are the sole source of the hormone insulin and BMPs have recently been implicated in pancreas development as well as control of adult @entity6 homeostasis. Lastly, we review the recently recognized role of BMPs in brown adipose tissue formation and their consequences for energy expenditure and adiposity. In summary, BMPs play a pivotal role in metabolism beyond their role in skeletal homeostasis. However, increased understanding of these pleiotropic functions also highlights the necessity of tissue-specific strategies when harnessing @entity10 action as a therapeutic target.

title: Bone morphogenetic proteins in inflammation, XXXX homeostasis and adipose tissue energy metabolism.

answer: @entity6


abstract: The predictive ability of different mathematical manipulations of condition correction factors in estimating total body clearance of @entity1 in acutely ill hospitalized @entity0 was evaluated. Fifty acutely ill @entity0 who were treated with constant @entity2 infusions were evaluated. Twenty-one @entity0 were evaluated prospectively. Initial serum @entity1 concentrations were ordered, and second concentrations were obtained at steady state. Twenty-nine @entity0 were evaluated retrospectively and were included if two steady-state serum @entity1 concentrations had been obtained. Each condition correction factor was determined by calculating the predicted normal clearance using a literature-derived clearance value and dividing it into the actual clearance obtained. The FDA condition correction factors were obtained by dividing the @entity1 dose recommended for @entity0 with a particular disease by the dose recommended for a normal @entity0 . Pearson correlation coefficients for 15 mathematical manipulations were used to examine the relationship between the predicted clearance and actual clearance. The predictability of @entity1 clearance using the mathematical manipulations decreased as the number of condition correction factors increased. The mean actual clearance for four @entity0 with no condition correction factors was only 2% greater than the mean standard clearance found in a previous study. The use of 0.041 L/hr/kg as a standard clearance appears justified for calculating initial @entity1 dosages in all @entity0 . @entity0 with only one condition correction factor may use this factor to adjust dosage, but when more than one factor is present, the use of the other manipulations studied may result in either subtherapeutic or toxic serum concentrations.

title: Prediction of XXXX clearance using condition correction factors.

answer: @entity1


abstract: A ten-year study of @entity0 has been reviewed in detail. The single most dominant variable was axillary nodal involvement. Four hundred and thirty @entity1 had nodal metastases, 58 @entity1 did not. Four hundred and thirty @entity1 with axillary nodal involvement had fiveand ten-year recurrence rates of 68 and 77%, while the survival rates were 41 and 21%, respectively. Life span was influenced by extent of @entity4 , being best for those with micrometastases only, and worse for those with four or more positive nodes. Skin @entity2 , @entity6 , or @entity5 in the positive node group were grave signs. Muscle invasion or node matting, however, did not appear to influence length of life. Postoperative prophylactic therapy did not appear to affect survival rates. Radiation therapy alone did not influence either local recurrence or survival rates. Not enough time has elapsed to evaluate the results of postoperative chemotherapy. @entity1 who underwent oophorectomy and radiation therapy appeared to do better, but the number of @entity1 was small. Of the 58 @entity1 without nodal invasion, 82% were alive at five years and 75% were alive at 10 years. Grave signs did not influence the survival rate in this group. While the majority of @entity1 with @entity3 had unfavorable variables, there were some @entity1 who demonstrated a low recurrence rate and a long survival time. Aggressive treatment should be designed to save those @entity1 who can be helped and to improve those @entity1 whose life expectancy is limited. There is no place for timid initial treatment whether by operation or by irradiation. It must be given with intent to cure even though palliation is most often attained.

title: Stage III XXXX . A detailed analysis.

answer: @entity0


abstract: Twenty-five of the initial computerized tomographic (CT) scans of 63 neonates had " @entity6 . These abnormalities included dilated ventricles, advanced @entity8 extending beyond the periventricular areas, and varieties of @entity5 . Thirty-six, with otherwise normal intracranial structures, were found to have localized periventricular frontal or frontooccipital areas of low attenuation. These areas were confined to the white matter of the periventricular area and have been identified by others as indicating " @entity7 ." In follow-up clinical studies on 26 of this latter groups, only two showed @entity1 . Seven CT scans were repeated; only one was abnormal. In this case, the @entity4 had disappeared, but were replaced by mild deep and @entity2 . The @entity0 then showed findings suggesting a mild @entity3 and psychomotor delay. Our findings suggest that periventricular low @entity4 in an otherwise normal CT scan are usually due to incomplete myelination or, at least, a transient abnormality. Periventricular low attenuation cannot be used as a diagnostic sign of @entity7 , nor does it necessarily suggest an unfavorable prognosis.

title: Periventricular low XXXX : a normal finding in computerized tomographic scans of neonates?

answer: @entity4


abstract: @entity9 provided a survival advantage compared with @entity8 in @entity0 with castration-resistant @entity4 refractory to @entity6 . Grade 3 to 4 (G3-4) @entity7 and @entity7 were relatively frequent in the registrative @entity10 Plus @entity3 Compared to @entity8 Plus @entity3 in Hormone Refractory Metastatic @entity4 (TROPIC) trial, but their incidence was lower in the Expanded Access Program (EAP). Although cumulative doses of @entity6 are associated with @entity1 , the effect of cumulative doses of @entity9 is unknown. In this retrospective review of prospectively collected data, the authors assessed "per cycle" incidence and predictors of @entity2 in the Italian cohort of the EAP, with a focus on the effect of cumulative doses of @entity9 .The study population consisted of 218 Italian @entity0 enrolled in the @entity9 EAP. The influence of selected variables on the most relevant adverse events identified was assessed using a Generalized Estimating Equations model at univariate and multivariate analysis."Per cycle" incidence of G 3 to 4 @entity7 was 8.7%, whereas @entity7 was reported in 0.9% of cycles. All events of @entity7 occurred during the first 3 cycles. Multivariate logistic regression analysis showed that higher prior dose of @entity9 was associated with decreased odds of having G3 to 4 @entity7 (OR=0.90; 95% CI: 0.86-0.93; P<0.01), @entity7 (OR=0.52; 95% CI: 0.34-0.81; P<0.01) and G3 to 4 @entity5 (OR=0.93; 95% CI: 0.86-1; P=0.07). @entity0 with a body surface area >2m presented increased odds of having G 3 to 4 @entity7 (OR=0.93; 95% CI: 0.86-1; P=0.07), but decreased odds of having G3 to 4 @entity5 .Among the @entity2 assessed, the authors did not identify any that appeared to be associated with a higher number of @entity9 cycles delivered. Prior cumulative dose was associated with reduced G3 to 4 @entity7 and @entity5 . The apparent protective effect associated with higher doses of @entity9 is likely to be affected by early dose reduction and early @entity2 -related treatment discontinuation. Because this analysis is limited by its retrospective design, prospective trials are required to assess the optimal duration of @entity9 treatment.

title: Lack of Cumulative XXXX Associated With @entity9 Use in @entity4 .

answer: @entity2